Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Esperion Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ESPR
Nasdaq
2834
https://www.esperion.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Esperion Therapeutics Inc
Esperion to Report First Quarter 2024 Financial Results on May 7
- Apr 23rd, 2024 12:00 pm
11 Best Low Price Pharma Stocks To Invest In
- Apr 21st, 2024 2:39 pm
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Apr 7th, 2024 6:45 pm
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
- Apr 1st, 2024 12:00 pm
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
- Mar 28th, 2024 3:30 pm
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Mar 26th, 2024 12:00 pm
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
- Mar 25th, 2024 8:00 pm
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Mar 22nd, 2024 10:26 pm
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Mar 22nd, 2024 7:10 pm
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
- Mar 22nd, 2024 3:04 pm
11 Best Small Cap Pharma Stocks to Invest In
- Mar 5th, 2024 1:28 am
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
- Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry
- Feb 29th, 2024 1:53 pm
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 2:44 pm
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
- Feb 28th, 2024 12:41 pm
Q4 2023 Esperion Therapeutics Inc Earnings Call
- Feb 28th, 2024 2:38 am
Esperion Therapeutics Inc (ESPR) Reports Strong Revenue Growth in Q4 and FY 2023
- Feb 27th, 2024 12:53 pm
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
- Feb 27th, 2024 12:20 pm
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 11:00 am
12 Best Medical Stocks to Buy Under $10
- Feb 27th, 2024 8:30 am
Scroll